Kiniksa Pharmaceuticals International (KNSA) 7th Annual Evercore ISI HealthCONx Healthcare Conference summary

Commercial performance and market strategy

• ARCALYST has achieved consistent net revenue growth each quarter since launch, with current market penetration at 11% of a 14,000-patient population.

• Disease awareness and targeted field force efforts are key levers for increasing penetration, with 2,550 unique prescribers and 640 repeat prescribers to date.

• Expansion of recognized centers of excellence and collaboration with the American Heart Association have increased specialist engagement, now at 15 centers.

• The field team has grown from 30 to 85 representatives, with future expansion decisions driven by data and value generation.

• Duration of therapy has increased from 6–9 months at launch to 27 months, reflecting the chronic nature of recurrent pericarditis and positive patient outcomes.

Product positioning and clinical development

• ARCALYST is positioned as a chronic therapy for patients with two or more recurrences, but is also used in first recurrence cases, which account for 15% of current patients.

• The company is focused on patients with the highest disease burden, while leveraging a broad label that allows for physician discretion in prescribing.

• Ongoing efforts include peer-to-peer education, digital marketing, and direct patient outreach to support prescriber growth and patient identification.

Pipeline and competitive landscape

• The phase II-B study of abiprubart (KPL-404) in Sjögren’s disease targets a large, underserved market with no approved therapies.

• Abiprubart differentiates through its CD40 mechanism, offering broader immunological action and a high-concentration liquid formulation for subcutaneous dosing, unlike competitors’ IV-only options.

• The ongoing phase II-B trial features two subcutaneous dosing regimens and a 24-week endpoint, with enrollment active but no disclosed timelines for data release.

• Early RA trial data support the potency and subcutaneous efficacy of abiprubart, with comparable pharmacodynamic effects to high-dose IV competitors.